160 related articles for article (PubMed ID: 1353706)
1. Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines.
Speicher LA; Barone L; Tew KD
Cancer Res; 1992 Aug; 52(16):4433-40. PubMed ID: 1353706
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.
Pienta KJ; Smith DC
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-72-S15-77. PubMed ID: 9346227
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of taxol on two human cancer cell lines.
Banerjee S; Fallis AG; Brown DL
Oncol Res; 1997; 9(5):237-48. PubMed ID: 9306431
[TBL] [Abstract][Full Text] [Related]
4. Interleukin 6 differentially potentiates the antitumor effects of taxol and vinblastine in U266 human myeloma cells.
Aoyama M; MacIsaac D; Bukowski RM; Ganapathi MK
Clin Cancer Res; 1998 Apr; 4(4):1039-45. PubMed ID: 9563900
[TBL] [Abstract][Full Text] [Related]
5. Increase of beta(III)- and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance.
Ranganathan S; Dexter DW; Benetatos CA; Chapman AE; Tew KD; Hudes GR
Cancer Res; 1996 Jun; 56(11):2584-9. PubMed ID: 8653701
[TBL] [Abstract][Full Text] [Related]
6. Modulation of endogenous beta-tubulin isotype expression as a result of human beta(III)cDNA transfection into prostate carcinoma cells.
Ranganathan S; McCauley RA; Dexter DW; Hudes GR
Br J Cancer; 2001 Sep; 85(5):735-40. PubMed ID: 11531260
[TBL] [Abstract][Full Text] [Related]
7. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
Nielsen LL; Lipari P; Dell J; Gurnani M; Hajian G
Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876
[TBL] [Abstract][Full Text] [Related]
8. Effects of microtubule inhibitors-taxol, vinblastine and estramustine on the growth and p53 gene expression in the hormone independent human prostatic JCA-1 cells.
Darby E; An S; Ng C; Hsieh TC; Mallouh C; Wu JM
Anticancer Res; 1996; 16(6B):3647-52. PubMed ID: 9042236
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of radiation response of prostatic carcinoma by taxol: therapeutic potential for late-stage malignancy.
Lokeshwar BL; Ferrell SM; Block NL
Anticancer Res; 1995; 15(1):93-8. PubMed ID: 7733649
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of paclitaxel and estramustine: preliminary activity in hormone-refractory prostate cancer.
Hudes GR; Obasaju C; Chapman A; Gallo J; McAleer C; Greenberg R
Semin Oncol; 1995 Jun; 22(3 Suppl 6):6-11. PubMed ID: 7597435
[TBL] [Abstract][Full Text] [Related]
11. Estramustine-binding protein (EMBP) content in four different cell lines and its correlation to estramustine induced metaphase arrest.
Eklöv S; Mahdy E; Wester K; Björk P; Malmström PU; Busch C; Nilsson S
Anticancer Res; 1996; 16(4A):1819-22. PubMed ID: 8712706
[TBL] [Abstract][Full Text] [Related]
12. Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol.
Rowinsky EK; Donehower RC; Jones RJ; Tucker RW
Cancer Res; 1988 Jul; 48(14):4093-100. PubMed ID: 2898289
[TBL] [Abstract][Full Text] [Related]
13. Resistance to the antimitotic drug estramustine is distinct from the multidrug resistant phenotype.
Speicher LA; Sheridan VR; Godwin AK; Tew KD
Br J Cancer; 1991 Aug; 64(2):267-73. PubMed ID: 1892755
[TBL] [Abstract][Full Text] [Related]
14. Micromolar taxol, with or without hyperthermia, induces mitotic catastrophe and cell necrosis in HeLa cells.
Michalakis J; Georgatos SD; Romanos J; Koutala H; Georgoulias V; Tsiftsis D; Theodoropoulos PA
Cancer Chemother Pharmacol; 2005 Dec; 56(6):615-22. PubMed ID: 16025289
[TBL] [Abstract][Full Text] [Related]
15. Immunofluorescent studies of the anti-microtubule effects of the anti-cancer drug estramustine.
Wang M; Tew KD; Stearns ME
Anticancer Res; 1987; 7(6):1165-71. PubMed ID: 3327449
[TBL] [Abstract][Full Text] [Related]
16. Combination chemotherapy of paclitaxel and cisplatin induces apoptosis with Bcl-2 phosphorylation in a cisplatin-resistant human epidermoid carcinoma cell line.
Sawada S; Mese H; Sasaki A; Yoshioka N; Matsumura T
Cancer Chemother Pharmacol; 2003 Jun; 51(6):505-11. PubMed ID: 12709826
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
[TBL] [Abstract][Full Text] [Related]
18. Estramustine-based chemotherapy.
Hudes G
Semin Urol Oncol; 1997 Feb; 15(1):13-9. PubMed ID: 9050135
[TBL] [Abstract][Full Text] [Related]
19. The effects of estramustine on metaphase and anaphase in DU 145 prostatic carcinoma cells.
Sheridan VR; Speicher LA; Tew KD
Eur J Cell Biol; 1991 Apr; 54(2):268-76. PubMed ID: 1879438
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of Taxol-induced cell death are concentration dependent.
Torres K; Horwitz SB
Cancer Res; 1998 Aug; 58(16):3620-6. PubMed ID: 9721870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
